| Year |
Title |
Altmetric |
| 2022
|
Lipase regulation of cellular fatty acid homeostasis as a Parkinson’s disease therapeutic strategy.
npj Parkinson's Disease.
8.
2022
|
|
| 2022
|
From bugs to bedside: functional annotation of human genetic variation for neurological disorders using invertebrate models.
Human Molecular Genetics.
31:R37-R46.
2022
|
|
| 2022
|
Systemic RNA Interference Defective (SID) genes modulate dopaminergic neurodegeneration in C. elegans.
PLoS Genetics.
18.
2022
|
|
| 2022
|
Amelioration of Alzheimer’s disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow.
Nature Biomedical Engineering.
6:76-93.
2022
|
|
| 2021
|
Neurodegenerative VPS41 variants inhibit HOPS function and mTORC1-dependent TFEB/TFE3 regulation.
EMBO Molecular Medicine.
13.
2021
|
|
| 2021
|
A conformational switch driven by phosphorylation regulates the activity of the evolutionarily conserved SNARE Ykt6
2021
|
|
| 2021
|
Conserved nicotine-activated neuroprotective pathways involve mitochondrial stress.
iScience.
24.
2021
|
|
| 2020
|
Therapeutic genetic variation revealed in diverse Hsp104 homologs.
eLife.
9:1-52.
2020
|
|
| 2020
|
Modeling neurodegeneration in Caenorhabditis elegans.
Disease Models and Mechanisms.
13.
2020
|
|
| 2019
|
Cyclized NDGA modifies dynamic α-synuclein monomers preventing aggregation and toxicity.
Scientific Reports.
9.
2019
|
|
| 2019
|
Genetic defects in mitochondrial dynamics in caenorhabditis elegans impact ultraviolet c radiation- and 6-hydroxydopamine-induced neurodegeneration.
International Journal of Molecular Sciences.
20.
2019
|
|
| 2019
|
Vacuolar protein sorting protein 41 (VPS41) at an intersection of endosomal traffic in neurodegenerative disease.
Neural Regeneration Research.
14:1210-1212.
2019
|
|
| 2019
|
Found in translation: The utility of C. elegans Alpha-Synuclein models of Parkinson’s disease.
Brain Sciences.
9.
2019
|
|
| 2019
|
ApoE-associated modulation of neuroprotection from Aβ-mediated neurodegeneration in transgenic Caenorhabditis elegans.
Disease Models and Mechanisms.
12.
2019
|
|
| 2018
|
Distinct functional roles of Vps41-mediated neuroprotection in Alzheimer's and Parkinson's disease models of neurodegeneration.
Human Molecular Genetics.
27:4176-4193.
2018
|
|
| 2018
|
No country for old worms: A systematic review of the application of C. elegans to investigate a bacterial source of environmental neurotoxicity in parkinson’s disease.
Metabolites.
8.
2018
|
|
| 2018
|
Correction to: The Small GTPase RAC1/CED-10 Is Essential in Maintaining Dopaminergic Neuron Function and Survival Against α-Synuclein-Induced Toxicity (Molecular Neurobiology, (2018), 55, 9, (7533-7552), 10.1007/s12035-018-0881-7).
Molecular Neurobiology.
55:7553-7554.
2018
|
|
| 2018
|
The Small GTPase RAC1/CED-10 Is Essential in Maintaining Dopaminergic Neuron Function and Survival Against α-Synuclein-Induced Toxicity.
Molecular Neurobiology.
55:7533-7552.
2018
|
|
| 2018
|
Alpha-synuclein inhibits Snx3-retromer-mediated retrograde recycling of iron transporters in S. cerevisiae and C. elegans models of Parkinson's disease.
Human Molecular Genetics.
27:1514-1532.
2018
|
|
| 2018
|
Gene-by-environment interactions that disrupt mitochondrial homeostasis cause neurodegeneration in C. elegans Parkinson's models.
Cell Death and Disease.
9.
2018
|
|
| 2017
|
Genetic and Pharmacological Discovery for Alzheimer's Disease Using Caenorhabditis elegans.
ACS Chemical Neuroscience.
8:2596-2606.
2017
|
|
| 2017
|
Dysregulation of the mitochondrial unfolded protein response induces non-apoptotic dopaminergic neurodegeneration in C. Elegans models of parkinson’s disease
2017
|
|
| 2017
|
NCEH-1 modulates cholesterol metabolism and protects against α-synuclein toxicity in a C. elegans model of Parkinson's disease.
Human Molecular Genetics.
26:3823-3836.
2017
|
|
| 2017
|
Dihydropyrimidine-Thiones and Clioquinol Synergize to Target β-Amyloid Cellular Pathologies through a Metal-Dependent Mechanism.
ACS Chemical Neuroscience.
8:2039-2055.
2017
|
|
| 2017
|
C. elegans as a model system to accelerate discovery for Parkinson disease.
Current Opinion in Genetics and Development.
44:102-109.
2017
|
|
| 2017
|
Meet our editorial board member.
Current Neuropharmacology.
15:195.
2017
|
|
| 2017
|
Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration.
Nature Neuroscience.
20:1560-1568.
2017
|
|
| 2016
|
Chemical compensation of mitochondrial phospholipid depletion in yeast and animal models of Parkinson's disease.
PLoS One.
11.
2016
|
|
| 2015
|
A bacterial metabolite induces glutathione-tractable proteostatic damage, proteasomal disturbances, and PINK1-dependent autophagy in C. elegans.
Cell Death and Disease.
6.
2015
|
|
| 2015
|
Glutaredoxin deficiency exacerbates neurodegeneration in C. Elegans models of Parkinson's disease.
Human Molecular Genetics.
24:1322-1335.
2015
|
|
| 2015
|
Phenazine derivatives cause proteotoxicity and stress in C. elegans.
Neuroscience Letters.
584:23-27.
2015
|
|
| 2014
|
RTCB-1 mediates neuroprotection via XBP-1 mRNA splicing in the unfolded protein response pathway
2014
|
|
| 2014
|
Phosphatidylethanolamine deficiency disrupts α-synuclein homeostasis in yeast and worm models of Parkinson disease
2014
|
|
| 2014
|
Calcineurin determines toxic versus beneficial responses to α-synuclein
2014
|
|
| 2014
|
The glycolytic enzyme, GPI, is a functionally conserved modifier of dopaminergic neurodegeneration in Parkinson's models.
Cell Metabolism.
20:145-157.
2014
|
|
| 2014
|
Clioquinol promotes the degradation of metal-dependent amyloid-ß (Aß) oligomers to restore endocytosis and ameliorate Aß toxicity
2014
|
|
| 2014
|
The effects of pdr1, djr1.1 and pink1 loss in manganese-induced toxicity and the role of α-synuclein in C. elegans
2014
|
|
| 2014
|
TorsinA rescues ER-associated stress and locomotive defects in C. elegans models of ALS.
Disease Models and Mechanisms.
7:233-243.
2014
|
|
| 2014
|
Protective Role of DNJ-27/ERdj5 in Caenorhabditis elegans models of human neurodegenerative diseases.
Antioxidants and Redox Signaling.
20:217-235.
2014
|
|
| 2014
|
Mitochondrial dysfunction, oxidative stress, and neurodegeneration elicited by a bacterial metabolite in a C. elegans Parkinson's model.
Cell Death and Disease.
5.
2014
|
|
| 2014
|
Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events.
Cell.
156:170-182.
2014
|
|
| 2013
|
Lysosomal impairment in Parkinson's disease.
Movement Disorders.
28:725-732.
2013
|
|
| 2013
|
Valproic acid ameliorates C. elegans dopaminergic neurodegeneration with implications for ERK-MAPK signaling.
Neuroscience Letters.
541:116-119.
2013
|
|
| 2013
|
Invertebrate models of dystonia.
Current Neuropharmacology.
11:16-29.
2013
|
|
| 2013
|
Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates α-Synuclein toxicity in neurons.
Science.
342:979-983.
2013
|
|
| 2012
|
Identification of novel ATP13A2 interactors and their role in α-synuclein misfolding and toxicity.
Human Molecular Genetics.
21:3785-3794.
2012
|
|
| 2012
|
A Predictable Worm: Application of Caenorhabditis elegans for Mechanistic Investigation of Movement Disorders.
Neurotherapeutics.
9:393-404.
2012
|
|
| 2012
|
The early-onset torsion dystonia-associated protein, torsinA, is a homeostatic regulator of endoplasmic reticulum stress response.
Human Molecular Genetics.
21:1201.
2012
|
|
| 2012
|
Functional analysis of VPS41-mediated neuroprotection in Caenorhabditis elegans and mammalian models of Parkinson's disease
2012
|
|
| 2012
|
Different 8-hydroxyquinolines protect models of TDP-43 protein, α-synuclein, and polyglutamine proteotoxicity through distinct mechanisms.
Journal of Biological Chemistry.
287:4107-4120.
2012
|
|
| 2011
|
Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast.
Science.
334:1241-1245.
2011
|
|
| 2011
|
Methodological strategies to evaluate functional effectors related to parkinson's disease through application of caenorhabditis elegans models.
Neuromethods.
61:31-53.
2011
|
|
| 2011
|
Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models.
Human Molecular Genetics.
20:3933-3942.
2011
|
|
| 2011
|
TorsinA participates in endoplasmic reticulum-associated degradation.
Nature Communications.
2.
2011
|
|
| 2011
|
Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.
Cell.
146:37-52.
2011
|
|
| 2011
|
Cell culture to investigate neurotoxicity and neurodegeneration utilizing Caenorhabditis elegans.
Neuromethods.
56:129-143.
2011
|
|
| 2011
|
Caenorhabditis elegans as a model system for identifying effectors of α-synuclein misfolding and dopaminergic cell death associated with Parkinson's disease.
ImmunoMethods.
53:220-225.
2011
|
|
| 2011
|
Modeling Dopamine Neuron Degeneration in Caenorhabditis elegans.
Methods in Molecular Biology.
793:129-148.
2011
|
|
| 2010
|
The early-onset torsion dystonia-associated protein, torsinA, displays molecular chaperone activity in vitro.
Cell Stress and Chaperones.
15:605-617.
2010
|
|
| 2010
|
Disinfecting dystonia? Drug discovery using worms identifies an antibiotic as a neuroprotective lead molecule for movement disorders.
Future Neurology.
5:473-476.
2010
|
|
| 2010
|
The early-onset torsion dystonia-associated protein, torsinA, is a homeostatic regulator of endoplasmic reticulum stress response.
Human Molecular Genetics.
19:3502-3515.
2010
|
|
| 2010
|
C. elegans as a model organism to investigate molecular pathways involved with Parkinson's disease.
Developmental Dynamics.
239:1282-1295.
2010
|
|
| 2010
|
Chemical enhancement of torsinA function in cell and animal models of torsion dystonia.
Disease Models and Mechanisms.
3:386-396.
2010
|
|
| 2010
|
Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models.
Disease Models and Mechanisms.
3:194-208.
2010
|
|
| 2010
|
VPS41, a protein involved in lysosomal trafficking, is protective in Caenorhabditis elegans and mammalian cellular models of Parkinson's disease.
Neurobiology of Disease.
37:330-338.
2010
|
|
| 2010
|
Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's disease.
Cell Death and Disease.
1.
2010
|
|
| 2010
|
Low-dose bafilomycin attenuates neuronal cell death associated with autophagy-lysosome pathway dysfunction.
Journal of Neurochemistry.
114:1193-1204.
2010
|
|
| 2009
|
Pharmacogenetic analysis reveals a post-developmental role for Rac GTPases in Caenorhabditis elegans GABAergic neurotransmission
2009
|
|
| 2009
|
Investigating bacterial sources of toxicity as an environmental contributor to dopaminergic neurodegeneration.
PLoS One.
4.
2009
|
|
| 2009
|
α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity.
Nature Genetics.
41:308-315.
2009
|
|
| 2009
|
Rapid selection of cyclic peptides that reduce α-synuclein toxicity in yeast and animal models.
Nature Chemical Biology.
5:655-663.
2009
|
|
| 2009
|
The microtubule-associated protein, NUD-1, exhibits chaperone activity in vitro.
Cell Stress and Chaperones.
14:95-103.
2009
|
|
| 2008
|
Traversing a wormhole to combat Parkinson's disease.
Disease Models and Mechanisms.
1:32-36.
2008
|
|
| 2008
|
Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease.
Neuroscience Letters.
439:129-133.
2008
|
|
| 2008
|
Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model
2008
|
|
| 2008
|
The Parkinson's disease protein α-synuclein disrupts cellular Rab homeostasis
2008
|
|
| 2008
|
Animal models for drug discovery in dystonia.
Expert Opinion on Drug Discovery.
3:83-97.
2008
|
|
| 2008
|
Application of a C. elegans dopamine neuron degeneration assay for the validation of potential parkinson's disease genes.
Journal of Visualized Experiments.
2008
|
|
| 2008
|
Generation of stable transgenic C. elegans using microinjection.
Journal of Visualized Experiments.
2008
|
|
| 2008
|
Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity..
Molecular Brain.
1:17.
2008
|
|
| 2008
|
Paradigms for pharmacological characterization of C. elegans synaptic transmission mutants.
Journal of Visualized Experiments.
2008
|
|
| 2007
|
Ubiquitin conjugating enzymes participate in polyglutamine protein aggregation.
BMC Molecular and Cell Biology.
8.
2007
|
|
| 2006
|
Genetic interactions among cortical malformation genes that influence susceptibility to convulsions in C. elegans.
Brain Research.
1120:23-34.
2006
|
|
| 2006
|
Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species
2006
|
|
| 2006
|
α-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models.
Science.
313:324-328.
2006
|
|
| 2005
|
Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans
2005
|
|
| 2004
|
MEC-2 is recruited to the putative mechanosensory complex in C. elegans touch receptor neurons through its stomatin-like domain.
Current Biology.
14:1888-1896.
2004
|
|
| 2004
|
Epileptic-like convulsions associated with LIS-1 in the cytoskeletal control of neurotransmitter signaling in Caenorhabditis elegans.
Human Molecular Genetics.
13:2043-2059.
2004
|
|
| 2004
|
An animal model to discern torsin function: suppression of protein aggregation in C. elegans..
Advances in neurology.
94:79-85.
2004
|
|
| 2004
|
Using Caenorhabditis elegans to probe toxicity of 1-alkyl-3-methylimidazolium chloride based ionic liquids.
Chemical Communications.
4:668-669.
2004
|
|
| 2003
|
Role of NudC, a dynein-associated nuclear movement protein, in mitosis and cytokinesis.
Journal of Cell Science.
116:1991-2003.
2003
|
|
| 2003
|
Suppression of polyglutamine-induced protein aggregation in Caenorhabditis elegans by torsin proteins.
Human Molecular Genetics.
12:307-319.
2003
|
|
| 2001
|
Evolutionarily conserved nuclear migration genes required for early embryonic development in Caenorhabditis elegans
2001
|
|
| 1996
|
Genetic interactions affecting touch sensitivity in Caenorhabditis elegans
1996
|
|
| 1995
|
Fungal lipopeptide mating pheromones: A model system for the study of protein prenylation.
Microbiology and Molecular Biology Reviews.
59:406-422.
1995
|
|
| 1994
|
Consequences of altered isoprenylation targets on a-factor export and bioactivity
1994
|
|
| 1994
|
Candida albicans gene encoding resistance to benomyl and methotrexate is a multidrug resistance gene.
Antimicrobial Agents and Chemotherapy.
38:648-652.
1994
|
|
| 1994
|
Molecular determinants of bioactivity of the Saccharomyces cerevisiae lipopeptide mating pheromone.
Journal of Biological Chemistry.
269:19817-19825.
1994
|
|
| 1993
|
Identification of a hyperactive mating pheromone of Saccharomyces cerevisiae.
Biochemical and Biophysical Research Communications.
197:1173-1178.
1993
|
|
| 1991
|
Significance of C-terminal cysteine modifications to the biological activity of the Saccharomyces cerevisiae a-factor mating pheromone.
Molecular and Cellular Biology.
11:3603-3612.
1991
|
|
| 1990
|
Total in vitro maturation of the Saccharomyces cerevisiae a-factor lipopeptide mating pheromone.
Biochemical and Biophysical Research Communications.
172:1310-1316.
1990
|
|
| 1990
|
Purification, properties, and titer of a hemolymph trophic factor in larvae and pupae of Manduca sexta.
Insect Biochemistry and Molecular Biology.
20:65-72.
1990
|
|
| 1989
|
Total synthesis of the lipopeptide a-mating factor ofSaccharomyces cerevisiae.
Biochemical and Biophysical Research Communications.
162:253-257.
1989
|
|
